MedPath
HSA Approval

ATRIZIN TABLET 10 MG

SIN13069P

ATRIZIN TABLET 10 MG

ATRIZIN TABLET 10 MG

March 22, 2005

GOLDPLUS UNIVERSAL PTE LTD

GOLDPLUS UNIVERSAL PTE LTD

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantGOLDPLUS UNIVERSAL PTE LTD
Licence HolderGOLDPLUS UNIVERSAL PTE LTD

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Pharmacy Only
HSA Singapore Classification

Formulation Information

TABLET

**Dosage and Administration** ![Atrizin Dosage Table 1](https://cdn.medpath.com/drug/dosage/20240520/42b37723baa387a112bb7bbabc2c4b8f.png) Cetirizine is safe for use in the elderly patients. Less frequent dosing is advised in patients with reduced creatinine clearance. In patients with renal insufficiency, dosage should be reduced to half the daily dose.

ORAL

Medical Information

**Indications** Atrizin® is indicated for the symptomatic relief of allergic manifestations, such as: - Seasonal allergic rhinitis - Perennial allergic rhinitis - Urticaria of allergic origin

**Contraindication** Cetirizine is contraindicated in patients who have shown hypersensitivity to it. It should not be administered to neonates, lactating mother and pregnant women.

R06AE07

cetirizine

Manufacturer Information

GOLDPLUS UNIVERSAL PTE LTD

BEXIMCO PHARMACEUTICALS LTD

Active Ingredients

CETIRIZINE HYDROCHLORIDE

10 MG

Cetirizine

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.